M.D. Anderson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).
M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.
M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.
Top-decile sponsor footprint
M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,692 total, page 36 of 54
Pegasys in Patients With Chronic Myeloid Leukemia (CML)
NCT01392170
A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
NCT01413178
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
NCT01375140
Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy
NCT01430351
Objective Assessment of Technical Skills in Cardiothoracic Surgery
NCT01433029
Effectiveness of Bronchoscopic Interventions for Malignant Airway Obstruction
NCT03326570
Mirror Grant - Toward an Understanding of Body Image Adaptation Following Surgical Treatment for Head and Neck Cancer
NCT01432132
Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas
NCT01329900
Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
NCT01253460
TPI 287 in Breast Cancer Metastatic to the Brain
NCT01332630
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
NCT01365156
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
NCT01421173
Phase II Evaluation of Exhaled Nitric Oxide (NO)
NCT01392144
Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
NCT01367275
Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma
NCT01301807
Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT01363128
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
NCT01258933
Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
NCT01272245
A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil
NCT01317550
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
NCT00968760
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
NCT01377389
Clearance Of Mucus In Stents (COMIS)
NCT01370278
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
NCT01248247
High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease
NCT01200329
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
NCT01110876
The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer
NCT01193530
Single Agent Armodafinil for Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer
NCT01330446
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer
NCT01263782
Nutrition and Physical Activity Intervention in Preventing Excess Weight Gain in Pediatric Patients With Leukemia or Lymphoma Treated With Prednisone and/or Dexamethasone
NCT05049785
Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor
NCT01277744
Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma
NCT01208103
Tolvaptan in Hyponatremic Cancer Patients
NCT01199198
Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients
NCT01169753
Stage I/II Nasal NK Cell Lymphoma
NCT01321008
Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
NCT01266057
Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies
NCT01339871
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy
NCT01180959
1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer
NCT01162785
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
NCT01200485
TEST: Registry for Endoscopic Head and Neck Surgery
NCT01412749
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
NCT01254864
Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma
NCT01198028
Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients
NCT01321879
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT01243190
Diabetic Treatment Adherence
NCT01318564
PKC412 and 5-Azacytidine
NCT01202877
Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma
NCT01092728
High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
NCT01266603
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
NCT01289457
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
NCT01263769
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 748 |
| Phase 2 | 971 |
| Phase 3 | 96 |
| Phase 4 | 28 |
Therapeutic Areas
What is open in the M.D. Anderson Cancer Center pipeline
549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).
Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).
Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.